18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative?
暂无分享,去创建一个
[1] M. O'Doherty,et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] E. Yoshikawa,et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[3] Klemens Scheidhauer,et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Lammertsma,et al. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non‐Hodgkin's lymphoma , 2003, British journal of haematology.
[5] A. Levis,et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. , 2006, Haematologica.
[6] Martin Hutchings,et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.
[7] Adriaan A. Lammertsma,et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[8] J. Leonard,et al. FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease , 2006, Cancer.
[9] R. Wahl,et al. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] Lotty Hooft,et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. , 2006, Haematologica.
[11] A. Kirby,et al. The role of FDG PET in the management of lymphoma: what is the evidence base? , 2007, Nuclear medicine communications.
[12] Emmanuel Itti,et al. Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.
[13] Emmanuel Itti,et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.
[14] Wolfgang A Weber,et al. Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Rowe,et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. , 2007, Blood.
[17] G. Jerusalem,et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.
[18] W. Wilson,et al. FDG-PET lymphoma demonstration project invitational workshop. , 2007, Academic radiology.
[19] P. Dupont,et al. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.